[Federal Register: December 10, 2003 (Volume 68, Number 237)]
[Notices]
[Page 68926-68931]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr10de03-91]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Studies To Determine the Prevalence of a History of Traumatic
Brain Injury (TBI) in an Institutionalized Population
Announcement Type: New.
Funding Opportunity Number: 04062.
Catalog of Federal Domestic Assistance Number: 93.136.
Key Dates:
Letter of Intent Deadline: January 9, 2004.
Application Deadline: February 18, 2003.
I. Funding Opportunity Description
Authority: This program is authorized under sections 391(a) and
301(a) of the Public Health Service Act (PHS Act) and 42 U.S.C. 241(a)
and 280b(a) as amended.
Purpose: The purpose of the program is to fund a cooperative
agreement to conduct pilot studies to investigate methods for
determining the prevalence of a history of traumatic brain injury (TBI)
in an institutionalized population. For purposes of this RFA,
``institutionalized'' refers to persons who are either incarcerated or
residing in a nursing home. Research on only one of these populations
should be proposed.
Anecdotal reports suggest that a very large proportion of the
prison population may have experienced one or more TBIs, with many of
them occurring prior to incarceration. The cognitive deficits that can
result from traumatic brain injuries often are not visible, and
behavioral and emotional problems associated with TBI may be
[[Page 68927]]
attributed to other causes. Thus, prisoners with TBI as well as prison
officials may not be aware of the signs, symptoms, and long term
problems resulting from TBI, and therefore may not seek or provide
appropriate treatment or other interventions. Better methods for
identifying incarcerated persons with a history of TBI and related
problems could lead to improved management of TBI in this population.
An estimated 20 to 30 percent of persons hospitalized with moderate
to severe TBI are discharged to nursing homes, including those for
long-term care. Not all of the persons with TBI who are discharged to
nursing homes are elderly, but little is known about the age
distribution and other characteristics of this population. Of note,
research on a small number of persons with TBI residing in long-term
nursing facilities found that, with the proper rehabilitation, they
recovered sufficient function to return home or live in a supported
community living environment. Better information on the number and
characteristics of persons with TBI living in nursing homes, including
their functional levels, would inform the development of policies to
ensure that they receive appropriate rehabilitation services that can
help them return to the community.
This program addresses the ``Healthy People 2010'' focus area of
Injury and Violence Prevention.
Measurable outcomes of the program will be in alignment with the
following performance goal for the National Center for Injury
Prevention and Control (NCIPC):
[sbull] Conduct a targeted program of research to reduce injury-
related death and disability.
Research Objectives
For research to identify TBI among prisoners:
[sbull] To develop valid and reliable measure(s) for ascertaining
the history of previous traumatic brain injuries (including those
occurring prior to or during incarceration) within a subgroup of the
incarcerated population (e.g., adult women or men in prison, or youth
in the juvenile justice system), or to validate an existing instrument
for use with this population.
[sbull] To use these measure(s) to determine the prevalence of a
history of TBI in an incarcerated population.
For research to identify persons with TBI in nursing homes:
[sbull] To determine the prevalence of persons admitted to nursing
homes with a diagnosis of TBI, including those for long-term care,
within a state, or alternatively a defined catchment area, for example,
multiple census tracts, multiple counties, or a metropolitan area.
[sbull] To determine the functional status and other
characteristics of a sample of persons with TBI in long-term care
facilities.
Activities
Awardee activities for this program are as follows:
[sbull] With assistance from the CDC, prepare a detailed research
protocol for Institutional Review Board (IRB) approval by all
cooperating institutions participating in the study, including CDC. The
protocol shall include but is not limited to the following: A detailed
description of a reliable and valid existing instrument(s) for use with
the proposed population, or the methods for developing such
instrument(s); recruitment and enrollment methods including the
informed consent process and consent forms; methods for data handling
and storage including methods for ensuring participant confidentiality;
data analysis methods; and plans for data dissemination. Specific
issues and approaches to conducting research in the proposed
institutional setting, including any prior experience, must be
described.
[sbull] Develop a detailed operations manual documenting study
methods.
[sbull] Train study personnel.
[sbull] Recruit study participants.
[sbull] Collect and enter the data.
[sbull] Provide case level data, without personal identifiers, to
the CDC for use in collaborative analyses.
[sbull] Analyze and interpret the data.
[sbull] Report study findings, including those in peer-reviewed
publications.
In a cooperative agreement, CDC staff is substantially involved in
the program activities, above and beyond routine grant monitoring.
CDC Activities for this program are as follows:
[sbull] Provide technical assistance where applicable and as
necessary for effective study planning and management.
[sbull] Assist in the development of a research protocol for
Institutional (IRB) review by all cooperating institutions
participating in the research. CDC will provide guidance about protocol
format and content as well as scientific and human subjects
considerations.
[sbull] The CDC IRB will review and approve the protocol initially
and on at least an annual basis until the research project is
completed.
[sbull] CDC staff will collaborate in the analysis of data and
reporting of findings by participating as co-authors in the preparation
of peer-reviewed publications.
[sbull] CDC staff will convene routine conference calls with the
recipient and conduct a site visit annually or as needed to review
progress.
II. Award Information
Type of Award: Cooperative agreement. CDC involvement in this
program is listed in the Activities Section above.
Fiscal Year Funds: 2004.
Approximate Total Funding: $ 300,000.
Approximate Number of Awards: Two.
Approximate Average Award: $ 150,000.
Floor of Award Range: $ 100,000.
Ceiling of Award Range: $200,000.
Anticipated Award Date: September 1, 2004.
Budget Period Length: 12 months.
Project Period Length: One year.
Throughout the project period, CDC's commitment to continuation of
awards will be conditioned on the availability of funds, evidence of
satisfactory progress by the recipient (as documented in required
reports), and the determination that continued funding is in the best
interest of the Federal government.
III. Eligibility Information
1. Eligible Applicants
Applications may be submitted by public and private nonprofit and
for profit organizations and by governments and their agencies, such
as:
[sbull] Public nonprofit organizations
[sbull] Private nonprofit organizations
[sbull] For profit organizations
[sbull] Small, minority, women-owned businesses
[sbull] Universities
[sbull] Colleges
[sbull] Research institutions
[sbull] Hospitals
[sbull] Community-based organizations
[sbull] Faith-based organizations
[sbull] Federally recognized Indian tribal governments
[sbull] Indian tribes
[sbull] Indian tribal organizations
[sbull] State and local governments or their bona fide agents (this
includes the District of Columbia, the Commonwealth of Puerto Rico, the
Virgin Islands, the Commonwealth of the Northern Marianna Islands,
American Samoa, Guam, the Federated States of Micronesia, the Republic
of the Marshall Islands, and the Republic of Palau)
[sbull] Political subdivisions of States (in consultation with
States)
A bona fide agent is an agency/organization identified by the State
as
[[Page 68928]]
eligible to submit an application under the State eligibility in lieu
of a state application. If you are applying as a bona fide agent of a
State or local government, you must provide a letter from the State or
local government as documentation of your status. Place this
documentation behind the first page of your application form.
2. Cost Sharing or Matching
Matching funds are not required for this program.
3. Other Eligibility Requirements
If your application is incomplete or non-responsive to the
requirements listed below, it will not be entered into the review
process. You will be notified that your application did not meet
submission requirements.
[sbull] Is there an appropriate degree of commitment and
cooperation from other participating parties as evidenced by letters of
support detailing the nature and extent of involvement? Letter(s) of
support from appropriate officials from departments of corrections,
nursing homes, or other agencies responsible for approving the use of
existing data sets containing information on these populations,
indicating approval for the research, must be included with the
application.
[sbull] Does the applicant describe research methods that are
feasible and appropriate for the corrections setting?
[sbull] Is there evidence of the experience and capacity for all
key staff members including Curriculum Vitae (CV) and position
descriptions?
[sbull] Does the research team include expert(s) with experience
conducting TBI research relevant to the proposed study?
[sbull] Are the investigators requesting a funding amount that is
greater than the upper ceiling of the award range?
[sbull] Principal investigators (PI's) are encouraged to submit
only one proposal in response to this program announcement. With few
exceptions (e.g., research issues needing immediate public health
attention), only one application per PI will be funded under this
announcement.
Note: Title 2 of the United States Code section 1611 states that
an organization described in section 501(c)(4) of the Internal
Revenue Code that engages in lobbying activities is not eligible to
receive Federal funds constituting an award, grant, or loan.
4. Individuals Eligible To Become Principal Investigators
Any individual with the skills, knowledge, and resources necessary
to carry out the proposed research is invited to work with their
institution to develop an application for support. Individuals from
underrepresented racial and ethnic groups as well as individuals with
disabilities are always encouraged to apply for CDC programs.
IV. Application and Submission Information
1. Address To Request Application Package
To apply for this funding opportunity, use application form PHS 398
(OMB number 0925-0001 rev. 5/2001). Forms and instructions are
available in an interactive format on the CDC Web site, at the
following Internet address: http://www.cdc.gov/od/pgo/forminfo.htm.
Forms and instructions are also available in an interactive format
on the National Institutes of Health (NIH) Web site at the following
Internet address: http://grants.nih.gov/grants/funding/phs398/phs398.html
.
If you do not have access to the Internet, or if you have
difficulty accessing the forms on-line, you may contact the CDC
Procurement and Grants Office Technical Information Management Section
(PGO-TIM) staff at: 770-488-2700. Application forms can be mailed to
you.
2. Content and Form of Application Submission
Letter of Intent (LOI)
CDC requests that you send a LOI if you intend to apply for this
program. Although the LOI is not required, not binding, and does not
enter into the review of your subsequent application, your LOI will be
used to gauge the level of interest in this program, and to allow CDC
to plan the application review. Your LOI must be written in the
following format:
[sbull] Maximum number of pages: Two;
[sbull] Font size: 12-point unreduced;
[sbull] Paper size: 8.5 by 11 inches;
[sbull] Page margin size: One inch;
[sbull] Single spaced;
[sbull] Printed only on one side of page;
[sbull] Written in English, no jargon.
Your LOI must contain the following information:
[sbull] Descriptive title of the proposed research;
[sbull] Name, address, e-mail, and telephone number of the
Principal Investigator;
[sbull] Names of other key personnel;
[sbull] Participating institutions;
[sbull] Number and title of this Program Announcement (PA).
Application
Follow the PHS 398 application instructions for content and
formatting of your application. For further assistance with the PHS 398
application form, contact GrantsInfo, telephone (301) 435-0714, email: GrantsInfo@nih.gov.
Your research plan should address activities to be conducted over
the entire project period.
You are required to have a Dun and Bradstreet Data Universal
Numbering System (DUNS) number to apply for a grant or cooperative
agreement from the Federal government. Your DUNS number must be entered
in item 11 of the face page of the PHS 398 application form. The DUNS
number is a nine-digit identification number, which uniquely identifies
business entities. Obtaining a DUNS number is easy and there is no
charge. To obtain a DUNS number, access http://www.dunandbradstreet.com
or call 1-866-705-5711. For more information, see the CDC Web site at:
http://www.cdc.gov/od/pgo/funding/pubcommt.htm.
3. Submission Dates and Times
LOI Deadline Date: January 9, 2004.
Application Deadline Date: February 18, 2004.
Explanation of Deadlines: Applications must be received in the CDC
Procurement and Grants Office by 4 p.m. eastern time on the deadline
date. If you send your application by the United States Postal Service
or commercial delivery service, you must ensure that the carrier will
be able to guarantee delivery of the application by the closing date
and time. If CDC receives your application after closing due to: (1)
Carrier error, when the carrier accepted the package with a guarantee
for delivery by the closing date and time, or (2) significant weather
delays or natural disasters, you will be given the opportunity to
submit documentation of the carriers guarantee. If the documentation
verifies a carrier problem, CDC will consider the application as having
been received by the deadline.
This announcement is the definitive guide on application submission
address and deadline. It supersedes information provided in the
application instructions. If your application does not meet the
deadline above, it will not be eligible for review, and will be
discarded. You will be notified that you did not meet the submission
requirements.
CDC will not notify you upon receipt of your application. If you
have a question about the receipt of your application, first contact
your courier. If you still have a question, contact the PGO-TIM staff
at: 770-488-2700. Before
[[Page 68929]]
calling, please wait two to three days after the application deadline.
This will allow time for applications to be processed and logged.
4. Intergovernmental Review of Applications
Executive Order 12372 does not apply to this program.
5. Funding Restrictions
Restrictions, which must be taken into account while writing your
budget, are as follows: none.
If you are requesting indirect costs in your budget, you must
include a copy of your indirect cost rate agreement. If your indirect
cost rate is a provisional rate, the agreement must be less than 12
months of age.
6. Other Submission Requirements
LOI Submission Address: Submit your LOI by express mail, delivery
service, fax, or e-mail to: Robin Forbes, Centers for Disease Control
and Prevention, National Center for Injury Prevention and Control, 4770
Buford Hwy, NE., Mailstop K-62, Atlanta, GA 30341. Telephone: 770-488-4037; fax: 770-488-1662; email: cipert@cdc.gov.
Application Submission Address: Submit the original and five copies
of your application by mail or express delivery service to: Technical
Information Management--PA 04062, CDC Procurement and Grants
Office, 2920 Brandywine Road, Atlanta, GA 30341.
Applications may not be submitted electronically at this time.
V. Application Review Information
1. Criteria
You are required to provide measures of effectiveness that will
demonstrate the accomplishment of the various identified objectives of
the cooperative agreement. Measures of effectiveness must relate to the
performance goals stated in the ``Purpose'' section of this
announcement. Measures must be objective and quantitative, and must
measure the intended outcome. These measures of effectiveness must be
submitted with the application and will be an element of evaluation.
The goals of CDC-supported research are to advance the
understanding of biological systems, improve the control and prevention
of disease, and enhance health. In the written comments, reviewers will
be asked to evaluate the application in order to judge the likelihood
that the proposed research will have a substantial impact on the
pursuit of these goals.
The scientific review group will address and consider each of the
following criteria in assigning the application's overall score,
weighting them as appropriate for each application.
The application does not need to be strong in all categories to be
judged likely to have major scientific impact and thus deserve a high
priority score. For example, an investigator may propose to carry out
important work that by its nature is not innovative, but is essential
to move a field forward.
The criteria are as follows:
Significance: Does this study address an important problem? If the
aims of the application are achieved, how will scientific knowledge be
advanced? What will be the effect of these studies on the concepts or
methods that drive this field?
Approach: Are the conceptual framework, design, methods, and
analyses adequately developed, well-integrated, and appropriate to the
aims of the project? Does the applicant acknowledge potential problem
areas and consider alternative tactics?
Innovation: Does the project employ novel concepts, approaches or
methods? Are the aims original and innovative? Does the project
challenge existing paradigms or develop new methodologies or
technologies?
Investigator: Is the investigator appropriately trained and well
suited to carry out this work? Is the work proposed appropriate to the
experience level of the principal investigator and other researchers
(if any)?
Environment: Does the scientific environment in which the work will
be done contribute to the probability of success? Does the proposed
experiment take advantage of unique features of the scientific
environment or employ useful collaborative arrangements? Is there
evidence of institutional support?
Additional Review Criteria: In addition to the above criteria, the
following items will be considered in the determination of scientific
merit and priority score:
[sbull] Does the applicant describe either (a) existing instruments
appropriate for use with the proposed population or (b) scientifically
sound plans for developing such instrument(s)?
[sbull] Does the applicant describe research methods appropriate
for a study in the proposed institutional setting?
[sbull] Are there adequate plans for data collection and data
management including security of data and assurance of participant
confidentiality?
[sbull] Is there a statistical analysis plan appropriate for the
study design?
[sbull] Does the applicant provide a detailed and appropriate
timeline for the study?
Protection of Human Subjects from Research Risks: Does the
application adequately address the requirements of Title 45 CFR Part 46
for the protection of human subjects? Not scored; however, an
application can be disapproved if the research risks are sufficiently
serious and protection against risks is so inadequate as to make the
entire application unacceptable.
Inclusion of Women and Minorities in Research: Does the application
adequately address the CDC Policy requirements regarding the inclusion
of woman, ethnic, and racial groups in the proposed research? This
includes: (1) The proposed plan for the inclusion of both sexes and
racial and ethnic minority populations for appropriate representation;
(2) the proposed justification when representation is limited or
absent; (3) a statement as to whether the design of the study is
adequate to measure differences when warranted; and (4) a statement as
to whether the plans for recruitment and outreach for study
participants include the process of establishing partnerships with
community(ies) and recognition of mutual benefits.
Inclusion of Children as Participants in Research Involving Human
Subjects
The NIH maintains a policy that children (i.e., individuals under
the age of 21) must be included in all human subjects research,
conducted or supported by the NIH, unless there are scientific and
ethical reasons not to include them. This policy applies to all initial
(Type 1) applications submitted for receipt dates after October 1,
1998.
All investigators proposing research involving human subjects
should read the ``NIH Policy and Guidelines'' on the inclusion of
children as participants in research involving human subjects that is
available at: http://grants.nih.gov/grants/funding/children/children.htm
.
Budget: The reasonableness of the proposed budget and the requested
period of support in relation to the proposed research. This
announcement does not use the modular budget format.
2. Review and Selection Process
Applications will be reviewed for completeness by the Procurement
and Grants Office (PGO) and for responsiveness for other eligibility
requirements by the National Center for Injury Prevention and Control.
Incomplete applications and applications that are non-responsive will
not advance through the review
[[Page 68930]]
process. You will be notified that you did not meet submission
requirements.
Applications that are complete and responsive to the PA will be
evaluated for scientific and technical merit by an appropriate peer
review group convened by the NCIPC in accordance with the review
criteria listed above. As part of the initial merit review, all
applications will:
[sbull] Undergo a process in which only those applications deemed
to have the highest scientific merit, generally the top half of the
applications under review, will be discussed and assigned a priority
score.
[sbull] Receive a written critique.
[sbull] Receive a second level review by the Science and Program
Review Subcommittee (SPRS) of the Advisory Committee for Injury
Prevention and Control (ACIPC).
Applications that are complete and responsive to the PA will be
subjected to a preliminary evaluation (streamline review) by a peer
review committee, the Initial Review Group (IRG) convened by NCIPC, to
determine if the application is of sufficient technical and scientific
merit to warrant further review by the IRG. CDC will withdraw from
further consideration applications judged to be noncompetitive and
promptly notify the principal investigator or program director and the
official signing for the applicant organization. Those applications
judged to be competitive will be further evaluated by a dual review
process.
1. The primary review will be a peer review conducted by the IRG.
All applications will be reviewed for scientific merit in accordance
with the review criteria listed above. Applications will be assigned a
priority score based on the National Institutes of Health (NIH) scoring
system of 100-500 points.
2. The secondary review will be conducted by the Science and
Program Review Subcommittee (SPRS) of NCIPC's Advisory Committee for
Injury Prevention and Control (ACIPC). The ACIPC Federal agency experts
will be invited to attend the secondary review, and will receive
modified briefing books (i.e., abstracts, strengths and weaknesses from
summary statements, and project officer's briefing materials). ACIPC
Federal agency experts will be encouraged to participate in
deliberations when applications address overlapping areas of research
interest, so that unwarranted duplication in federally-funded research
can be avoided and special subject area expertise can be shared. The
NCIPC Division Associate Directors for Science (ADS) or their designees
will attend the secondary review in a similar capacity as the ACIPC
Federal agency experts to assure that research priorities of the
announcement are understood and to provide background regarding current
research activities. Only SPRS members will vote on funding
recommendations, and their recommendations will be carried to the
entire ACIPC for voting by the ACIPC members in closed session. If any
further review is needed by the ACIPC, regarding the recommendations of
the SPRS, the factors considered will be the same as those considered
by the SPRS.
The committee's responsibility is to develop funding
recommendations for the NCIPC Director based on the results of the
primary review, the relevance and balance of proposed research relative
to the NCIPC programs and priorities, and to assure that unwarranted
duplication of federally-funded research does not occur. The secondary
review committee has the latitude to recommend to the NCIPC Director,
to reach over better-ranked proposals in order to assure maximal impact
and balance of proposed research. The factors to be considered will
include:
a. The results of the primary review including the application's
priority score as the primary factor in the selection process.
b. The relevance and balance of proposed research relative to the
NCIPC programs and priorities.
c. The significance of the proposed activities in relation to the
priorities and objectives stated in ``Healthy People 2010,'' the
Institute of Medicine report, ``Reducing the Burden of Injury,'' and
the ``CDC Injury Research Agenda.''
Award Criteria: Criteria that will be used to make award decisions
include:
[sbull] Scientific merit (as determined by peer review)
[sbull] Availability of funds
[sbull] Programmatic priorities
VI. Award Administration Information
1. Award Notices
Successful applicants will receive a Notice of Grant Award (NGA)
from the CDC Procurement and Grants Office. The NGA shall be the only
binding, authorizing document between the recipient and CDC. The NGA
will be signed by an authorized Grants Management Officer, and mailed
to the recipient fiscal officer identified in the application.
2. Administrative and National Policy Requirements
45 CFR part 74 and 92.
For more information on the Code of Federal Regulations, see the
National Archives and Records Administration at the following Internet
address: http://www.access.gpo.gov/nara/cfr/cfr-table-search.html.
The following additional requirements apply to this project:
[sbull] AR-1--Human Subjects Requirements
[sbull] AR-2--Requirements for Inclusion of Women and Racial and Ethnic
Minorities in Research
[sbull] AR-6--Patient Care
[sbull] AR-8--Public Health System Reporting Requirements
[sbull] AR-9--Paperwork Reduction Act Requirements
[sbull] AR-10--Smoke-Free Workplace Requirements
[sbull] AR-11--Healthy People 2010
[sbull] AR-12--Lobbying Restrictions
[sbull] AR-13--Prohibition on Use of CDC Funds for Certain Gun Control
Activities
[sbull] AR-14--Accounting System Requirements
[sbull] AR-15--Proof of Non-Profit Status
[sbull] AR-21--Small, Minority, and Women-Owned Business
[sbull] AR-22--Research Integrity
[sbull] AR-23--States and Faith-Based Organizations
[sbull] AR-24--Health Insurance Portability and Accountability Act
Requirements
[sbull] AR-25--Release and Sharing of Data
Starting with the December 1, 2003, receipt date, all NCIPC
funded investigators seeking more than $500,000 in total costs in a
single year are expected to include a plan describing how the final
research data will be shared/released or explain why data sharing is
not possible. Details on data sharing/release, including the
timeliness and name of the project data steward, should be included
in a brief paragraph immediately following the Research Plan Section
of the PHS 398 form. References to data sharing/release may also be
appropriate in other sections of the application (e.g. background
and significance, human subjects requirements, etc.) The content of
the data sharing/release plan will vary, depending on the data being
collected and how the investigator is planning to share the data.
The data sharing/release plan will not count towards the application
page limit and will not factor into the determination of scientific
merit or priority scores. Investigators should seek guidance from
their institutions on issues related to institutional policies,
local IRB rules, as well as local, State and Federal laws and
regulations, including the Privacy Rule.
Further detail on the requirements for addressing data sharing
in applications for NCIPC funding may be obtained by contacting
NCIPC program staff or visiting the NCIPC Internet Web site: at
http://www.cdc.gov/ncipc/osp/sharing_policy.htm.
Additional information on these requirements can be found on the
CDC Web site at the following Internet address: http://www.cdc.gov/od/pgo/funding/ARs.htm
.
[[Page 68931]]
3. Reporting
You must provide CDC with an original, plus two copies of the
following reports:
1. Interim progress report, (PHS 2590, OMB Number 0925-0001, rev.
5/2001) no less than 90 days before the end of the budget period. The
progress report will serve as your non-competing continuation
application, and must contain the following elements:
a. Current Budget Period Activities Objectives.
b. Current Budget Period Financial Progress.
c. New Budget Period Program Proposed Activity Objectives.
d. Detailed Line-Item Budget and Justification.
e. Additional Requested Information.
2. Financial status report, no more than 90 days after the end of
the budget period.
3. Final financial and performance reports, no more than 90 days
after the end of the project period.
These reports must be sent to the Grants Management Specialist
listed in the ``Agency Contacts'' section of the announcement.
VII. Agency Contacts
For general questions about this announcement, contact: Technical
Information Management Section, PA04062, CDC Procurement and
Grants Office, 2920 Brandywine Road, Atlanta, GA 30341. Telephone: 770-
488-2700.
For scientific/research program technical assistance, contact:
William K. Ramsey, Project Officer, Division of Injury and Disability
Outcomes and Programs, Centers for Disease Control and Prevention, 4770
Buford Highway, Mail Stop F-41, Chamblee, GA 30341. Telephone: 770-488-1226; e-mail: BRamsey1@cdc.gov.
For questions about peer review, contact: Gwendolyn Cattledge,
Scientific Review Administrator, Centers for Disease Control and
Prevention, National Center for Injury Prevention and Control, 4770
Buford Highway, NE., MailStop K-02, Atlanta, GA 30341. Telephone: 770-488-1430; e-mail: gxc8@cdc.gov.
For budget assistance, contact: Angie Nation, Grants Management
Specialist, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341. Telephone: 770-488-2719; e-mail: aen4@cdc.gov.
Dated: December 4, 2003.
Edward Schultz,
Acting Director, Procurement and Grants Office, Centers for Disease
Control and Prevention.
[FR Doc. 03-30583 Filed 12-9-03; 8:45 am]
BILLING CODE 4163-18-P